Literature DB >> 7617822

Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.

K M Hegadoren1, M T Martin-Iverson, G B Baker.   

Abstract

Spontaneous behaviours were assessed in freely moving rats after treatment with equimolar doses of drugs that share a basic amphetamine structure. The drugs used included a psychomotor stimulant [(+)-amphetamine (AMPH)], an hallucinogen [para-methoxyamphetamine (PMA)] and the entactogens 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-N-ethylamphetamine (MDE). A detailed analysis of the frequency and duration of 30 different behaviours and the temporal organization of the behaviours was conducted in addition to measuring motor activity with an automated device. Levels of the biogenic amines and their acid metabolites in discrete brain regions and brain drug levels were also obtained. The automated motor activity measures discriminated among entactogens, the stimulant and the hallucinogen, but failed to distinguish between the hallucinogen and vehicle. Principal components analysis and cluster analysis of the frequencies and durations of the behaviours did not improve the classification of the drugs over the automated motor activity measures. Only the cluster analysis of the transitions between individual behaviours succeeded in differentiating the drug classes from each other and from vehicle treatment. All the behavioural measures classified one entactogen (MDE) as an hallucinogen. Cortical 5-hydroxytryptamine (5-HT) measures grouped MDE with the other entactogens but did not distinguish AMPH from vehicle. However, striatal dopamine measures differentiated AMPH from vehicle treatment. Variations in the durations of behavioural effects across drugs were associated with large differences in drug levels 3 h after injection. Although the neurochemical data provided a classification system that most closely parallels human subjective effects of these drugs, both the neurochemical and the behavioural measures supported the existence of an entactogen class distinct from a psychomotor stimulant and an hallucinogen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617822     DOI: 10.1007/BF02245958

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

1.  Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat.

Authors:  L J Spanos; B K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  1989-04       Impact factor: 3.533

2.  Amphetamine as a model for hyperactivity in the rat.

Authors:  S Norton
Journal:  Physiol Behav       Date:  1973-08

3.  On the discontinous nature of behavior.

Authors:  S Norton
Journal:  J Theor Biol       Date:  1968-11       Impact factor: 2.691

4.  Effect of para-methoxyamphetamine on catecholamine metabolism in the mouse brain.

Authors:  R J Hitzemann; H H Loh; E F Domino
Journal:  Life Sci I       Date:  1971-10-01

Review 5.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

6.  MDA: a psychoactive agent with dual stimulus effects.

Authors:  R A Glennon; R Young
Journal:  Life Sci       Date:  1984-01-23       Impact factor: 5.037

7.  Further investigation of the discriminative stimulus properties of MDA.

Authors:  R A Glennon; R Young
Journal:  Pharmacol Biochem Behav       Date:  1984-04       Impact factor: 3.533

8.  (+/-)3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats.

Authors:  D J Mokler; S E Robinson; J A Rosecrans
Journal:  Eur J Pharmacol       Date:  1987-06-19       Impact factor: 4.432

9.  The identification of LSD-like hallucinogens using the chronic spinal dog.

Authors:  W R Martin; D B Vaupel; M Nozaki; L D Bright
Journal:  Drug Alcohol Depend       Date:  1978-03       Impact factor: 4.492

10.  3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine.

Authors:  D J McKenna; X M Guan; A T Shulgin
Journal:  Pharmacol Biochem Behav       Date:  1991-03       Impact factor: 3.533

View more
  3 in total

1.  Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats.

Authors:  Tomáš Páleníček; Michaela Fujáková; Martin Brunovský; Jiří Horáček; Ingmar Gorman; Marie Balíková; Lukáš Rambousek; Kamila Syslová; Petr Kačer; Petr Zach; Věra Bubeníková-Valešová; Filip Tylš; Anna Kubešová; Jana Puskarčíková; Cyril Höschl
Journal:  Psychopharmacology (Berl)       Date:  2012-07-29       Impact factor: 4.530

2.  MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology.

Authors:  P Sáez-Briones; A Hernández
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

3.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.